TITLE

THERAPEUTIC USE OF HUMAN EMBRYONIC STEM CELLS

AUTHOR(S)
Aznar, Justo; Navarro-Illana, Pedro
PUB. DATE
November 2014
SOURCE
Acta Bioéthica;2014, Vol. 20 Issue 2, p291
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
99427658

 

Related Articles

  • Plasma polymer coatings to aid retinal pigment epithelial growth for transplantation in the treatment of age related macular degeneration. Kearns, Victoria; Mistry, Anita; Mason, Sharon; Krishna, Yamini; Sheridan, Carl; Short, Robert; Williams, Rachel // Journal of Materials Science: Materials in Medicine;Aug2012, Vol. 23 Issue 8, p2013 

    Subretinal transplantation of functioning retinal pigment epithelial (RPE) cells grown on a synthetic substrate is a potential treatment for age-related macular degeneration (AMD), a common cause of irreversible vision loss in developed countries. Plasma polymers give the opportunity to tailor...

  • Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration.  // Biomedical Market Newsletter;1/21/2012, Vol. 21, p1 

    The article informs that Advanced Cell Technology Inc., a regenerative medicine provider has announced that its institutional review board (IRB) has approved Wills Eye Institute of Philadelphia as the site for the clinical trial. The trial will be based on dry age-related macular degeneration...

  • Advanced Cell Technology to Present at the 2012 Bio Intl Convention and the Clinical Outlooks for Regenerative Medicine Meeting.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that Advanced Cell Technology Inc. will be presenting at the 2012 Bio International Convention and Clinical Outlooks for Regenerative Medicine meeting, both to be held in Boston, Massachusetts on June 19, 2012. Topics of the presentation include company's three ongoing...

  • ACT Announces First Dry AMD Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived RPE Cells.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article informs that a fourth patient has been treated in the Advanced Cell Technology Inc.'s Phase I/II clinical trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed...

  • Telescopic mirror implant may help improve vision in AMD patients. Cimberle, Michela // Ocular Surgery News Europe;Apr2010, Vol. 21 Issue 4, p22 

    The article discusses the findings of a study presented by surgeon Isaac Lipshitz at the winter meeting of the European Society of Cataract and Refractive Surgeons (ESCRS), which indicated that OptoLight's Lipshitz Macular Implant (LMI) provides an option for treating patients with macular...

  • Early Success Reported in hESC Trial for Macular Degeneration. Moran, Nuala // BioWorld Today;1/25/2012, Vol. 23 Issue 16, p1 

    The article reports that early signs of efficacy of human embryonic stem cell (hESC)-derived retinal pigment epithelium cells in treating macular degeneration were demonstrated in a trial at Moorfields Eye Hospital in London, England. The trial was conducted by Advanced Cell Technology (ACT)...

  • Clinic Roundup.  // BioWorld Today;4/25/2012, Vol. 23 Issue 80, p3 

    This section offers news briefs on clinical trials. Authorization was granted to Advanced Cell Technology Inc. by an independent data and safety monitoring board to proceed with its testing of retinal pigment epithelial cells in macular degeneration. Patient enrollment was completed by DUSA...

  • Sight preserved in AMD patients receiving steroid derivative. Charters, Lynda // Ophthalmology Times;11/1/2003, Vol. 28 Issue 31, p59 

    Reports that findings from a phase II/III study conducted by the Anecortave Acetate Clinical Study Group indicate that anecortave acetate can have a positive impact on the treatment of patients with age-related macular degeneration (AMD). Long-term benefits that anecortave acetate can provide...

  • Vascular targeting to start phase I/II trial for patients with wet AMD.  // Ophthalmology Times;8/15/2003, Vol. 28 Issue 16, p30 

    Focuses on the start of the phase I/II clinical trial of the vascular targeting agent Combretastatin A4 Prodrug for wet age-related macular degeneration (AMD). Treatment of cancer in patients with wet AMD.

Share

Other Topics